Journal of Clinical Trials
Open Access

Department of Respiratory and Critical Care Medicine, Dongfang Hospital of Xiamen University, Fuzhou General Hospital of Fujian Medical University, The 900th Hospital of the Joint Logistic Support Force, Fuzhou, China

Publications

• Research   
  Lung Adenocarcinoma with Active Aulmonary Tuberculosis: A Case Report of Successful Immunotherapy and Systematical Review
  Author(s): Jinhe Xu, Xiuhua Lin, Wei Liu, Jia Ye, Zongyang Yu*, Feilai Xie, Huimin Deng and Ming Deng
  
  Background: Immune Checkpoint Inhibitors (ICIs) have become widely used in the treatment of several malignancies, and get better clinical benefits in some patients with Non-Small Cell Lung Cancer (NSCLC). However, in most of high quality clinical Randomized Controlled Trial (RCT) studies, only selected patients are needed. In Real-World Study (RWS), patients contracted simultaneously with NSCLC and Tuberculosis is common. TB reactivation during ICIs use is increasingly recognized and reported. Whether ICIs can be used in anti-tumor in patients with TB is rarely seen. Case presentation: Herein, we present a 67-year-old male active tuberculosis complicated with advanced Non-Small Cell Lung Cancer (NSCLC) ALK-negative, EGFR wild, and PD-L1 Immune Histochemistry (IHC) strongly positive in 60%-90% of tumor cells, on ongoing treatment with Pembrol.. View More»
  

  Abstract HTML PDF